Researchers are exploring the use of radiogenomics and multi-omics analysis to improve the diagnosis and prognosis of glioblastoma, a type of brain cancer. Studies are investigating the potential of mpMRI scans and machine learning approaches to predict MGMT promoter methylation status, which is associated with treatment response. The field is rapidly advancing, with various approaches being developed and reviewed, including radiomics, deep learning, and artificial intelligence.